Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176878 | 1.00 | TDP1 (0.56) | TDP1TSHRSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL1259532 | 0.83 | RAB9A (0.59) | TDP1SMN1; SMN2ALDH1A1NPC1RECQL | |
| SCHEMBL1259536 | 0.83 | RAB9A (0.59) | TDP1SMN1; SMN2ALDH1A1NPC1RECQL | |
| SCHEMBL29229957 | 0.79 | TDP1 (0.69) | TDP1TSHRSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL29391066 | 0.78 | TDP1 (0.69) | TDP1TSHRSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL943484 | 0.78 | TDP1 (0.69) | TDP1TSHRSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL19006811 | 0.76 | TDP1 (0.64) | TDP1TSHRSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3842471 | 0.75 | TDP1 (0.58) | TDP1TSHRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL28077500 | 0.75 | TDP1 (0.58) | TDP1TSHRSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL23421580 | 0.74 | TDP1 (0.56) | TDP1TSHRSMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251418-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2345636-A1 | CASR AGONIST | Ajinomoto Co., Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251418-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | TDP1 3524/4885TSHR 481/4885SMN1; SMN2 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.